Cagrilintide is a long-acting synthetic analogue of amylin, a 37-amino acid peptide co-secreted with insulin from pancreatic beta cells. Natural amylin plays a role in regulating postprandial glucose excursions, gastric emptying, and satiety signaling through amylin receptors in the area postrema and hypothalamus. Cagrilintide has been engineered with structural modifications to extend its half-life suitable for once-weekly administration in research protocols.
Research has examined Cagrilintide for its potential to complement GLP-1 receptor agonism by acting through a complementary satiety pathway. Studies have explored amylin receptor agonism as a distinct mechanism for reducing food intake that operates through different hypothalamic circuits than GLP-1R signaling. Preclinical research has examined cagrilintide’s effects on body weight, food consumption patterns, and gastric emptying rates in animal models.
Clinical research programs have studied Cagrilintide both as a monotherapy and in combination with semaglutide (as the CagriSema combination), generating pharmacokinetic and pharmacodynamic data. Research has explored synergistic effects of dual amylin and GLP-1 receptor engagement on metabolic outcomes. Its unique mechanism makes it an important research tool for studying amylin biology in metabolic contexts.
For research use only. Not for human consumption. Iron Prairie Labs products are intended for qualified researchers and laboratory use only.
